01—Abstract
Summary
Summary of the 8-K filed August 27, 2025. Cited figures are marked; the original filing is the authoritative source.
On August 27, 2025, Cencora (NYSE: COR) announced a board leadership transition: Lead Independent Director D.
Mark Durcan will become Chairman of the Board effective October 1, 2025, succeeding Steven H. Collis. Collis, who has chaired the board since 2016 and was Executive Chairman since October 2024, will retire from the Board and as Executive Chairman at the end of the fiscal year ending September 30, 2025.
The filing states his retirement was not due to any disagreement with the Company on operations, policies, or practices. As a result of Collis's departure, the Board will shrink from 11 to 10 directors upon his retirement. Durcan has served on the board since 2015 and as Lead Independent Director since 2023, and is the retired CEO of Micron Technology.
CEO Robert P. Mauch framed the appointment as supporting the company's pharmaceutical-centric strategy and its track record of sustainable long-term growth. From an investor standpoint, this is primarily a governance update rather than a financial disclosure: the filing contains no earnings, guidance, or financial metrics.
The transition is orderly and planned, since Collis's exit was previously reported, and it keeps a director with long board tenure in the chair role. Investors may watch for any changes in board committee leadership or the Lead Independent Director role that will be vacated by Durcan's promotion.
02—Key points
Key Highlights
- D. Mark Durcan, a director since 2015 and Lead Independent Director since 2023, will become Chairman of the Board effective October 1, 2025.
- Steven H. Collis will retire as Executive Chairman and as a director at the end of fiscal year 2025 (fiscal year ending September 30, 2025), ending his role as Chairman held since 2016.
- The Board will decrease from 11 to 10 directors upon Collis's retirement.
- The filing states Collis's retirement was not due to any disagreement with the Company on operations, policies, or practices.
- Durcan is the retired CEO of Micron Technology (2012–2017) and currently serves as a director of ASML Holding NV.
- CEO Robert P. Mauch said the appointment supports Cencora's pharmaceutical-centric strategy and long-term growth track record.
- The filing contains no financial results, guidance, or quantitative metrics; the disclosure is governance-related under Items 5.02 and 7.01.
03—Questions
Frequently Asked Questions
Who is replacing Steven Collis as Chairman of Cencora's Board?
D. Mark Durcan, currently the Lead Independent Director, will become Chairman of the Board effective October 1, 2025. He has been a director since September 2015 and Lead Independent Director since March 2023.
Is Steven Collis leaving the company or only the board?
The filing says Collis will retire as Executive Chairman and as a director effective at the end of fiscal year 2025 (September 30, 2025). The filing does not state any change to other roles, but he previously served as CEO from 2011 to 2024.
Why is Collis leaving, and is there any dispute?
The filing states that his retirement was not due to any disagreement with the Company on any matter relating to its operations, policies, or practices. The retirement was previously reported and was part of a planned one-year Executive Chairman term.
Does this change the size of the board?
Yes. The Board will be reduced from 11 directors to 10 directors, effective upon Collis's retirement.
Does this announcement affect Cencora's financial outlook?
The 8-K contains no financial results, guidance, or quantitative data. It is a governance update, so it does not by itself indicate any change to Cencora's financial performance or outlook.
04—Continue